The Johns Hopkins Kimmel Cancer Center’s Division of Hematologic Malignancies and Bone Marrow Transplant (HMBMT) is home to innovative research dedicated to alleviating the suffering of the thousands of patients who are diagnosed annually with blood, bone marrow, and lymphatic cancers.
For many, our innovations have transformed the trajectory of treatment. It was over 50 years ago that our scientists initiated seminal studies that transformed bone marrow transplantation into standard of care for these forms of cancer. We also developed a protocol of post-transplant cyclophosphamide to prevent rejection in bone marrow transplantation, and as a cure for malignant and non-malignant blood disorders.
We haven’t stopped there. Our contributions to bettering the lives of patients and families faced with a life altering diagnosis of leukemia, lymphoma or multiple myeloma include (and are not limited to):
Experimental Drug Development Approach Points to Better Targeted Therapies for Treatment-Resistant Leukemia
Generous donors have transformed visionary laboratory concepts, like those described, into clinical realities. Though we take pride in all that has been accomplished, we are cognizant that much more needs to be done to help those facing a life-altering diagnosis. Please join our ambitious path forward by investing in our efforts to improve diagnostics, reduce therapeutic toxicities and prevent recurrence for those confronted with the challenges of leukemia, lymphoma or multiple myeloma.
If you would like to learn more about how you can help, please contact Anne Kennan in our development office at akennan1@jhmi.edu.
Signing in with your Johns Hopkins account will automatically fill in your name and address information in the next step of making your submission. Selecting Continue as Guest will allow you to submit without signing in to an existing Johns Hopkins account.